Operating Expenses Summary of Novavax, Inc.

Novavax, Inc.'s latest annual operating expenses in 2023 was 779.12 Million USD , down -41.9% from previous year.
Novavax, Inc.'s latest quarterly operating expenses in 2024 Q2 was 208.24 Million USD , up 16.03% from previous quarter.
Novavax, Inc. reported a annual operating expenses of 1.34 Billion USD in annual operating expenses 2022, down -52.66% from previous year.
Novavax, Inc. reported a annual operating expenses of 2.83 Billion USD in annual operating expenses 2021, up 217.47% from previous year.
Novavax, Inc. reported a quarterly operating expenses of 179.47 Million USD for 2024 Q1, down -36.35% from previous quarter.
Novavax, Inc. reported a quarterly operating expenses of 281.99 Million USD for 2023 Q4, up 478.24% from previous quarter.

Annual Operating Expenses Chart of Novavax, Inc. (2023 - 1996)

Historical Annual Operating Expenses of Novavax, Inc. (2023 - 1996)

Year	Operating Expenses	Operating Expenses Growth
2023	779.12 Million USD	-41.9%
2022	1.34 Billion USD	-52.66%
2021	2.83 Billion USD	217.47%
2020	892.31 Million USD	501.86%
2019	148.25 Million USD	-28.79%
2018	208.2 Million USD	2.62%
2017	202.88 Million USD	-28.68%
2016	284.46 Million USD	47.02%
2015	193.48 Million USD	94.73%
2014	99.36 Million USD	52.57%
2013	65.12 Million USD	75.79%
2012	37.04 Million USD	26.6%
2011	29.26 Million USD	-24.65%
2010	38.83 Million USD	2.99%
2009	37.7 Million USD	6.45%
2008	35.42 Million USD	12.23%
2007	31.56 Million USD	38.33%
2006	22.81 Million USD	111.9%
2005	10.76 Million USD	-63.17%
2004	29.23 Million USD	13.39%
2003	25.78 Million USD	-21.88%
2002	33 Million USD	12.76%
2001	29.26 Million USD	85.12%
2000	15.81 Million USD	155.02%
1999	6.2 Million USD	0.0%
1998	6.2 Million USD	10.71%
1997	5.6 Million USD	-5.08%
1996	5.9 Million USD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	208.24 Million USD	16.03%
2024 Q1	179.47 Million USD	-36.35%
2023 Q4	281.99 Million USD	478.24%
2023 Q3	48.76 Million USD	-84.43%
2023 Q2	313.19 Million USD	15.04%
2023 Q1	272.25 Million USD	-22.2%
2023 FY	779.12 Million USD	-41.9%
2022 Q3	427.17 Million USD	7.38%
2022 FY	1.34 Billion USD	-52.66%
2022 Q1	479.47 Million USD	-54.21%
2022 Q2	397.8 Million USD	-17.03%
2022 Q4	349.94 Million USD	-18.08%
2021 Q1	655.86 Million USD	41.8%
2021 Q3	485.98 Million USD	-24.52%
2021 Q2	643.84 Million USD	-1.83%
2021 FY	2.83 Billion USD	217.47%
2021 Q4	1.04 Billion USD	115.47%
2020 FY	892.31 Million USD	501.86%
2020 Q2	52.56 Million USD	100.06%
2020 Q3	350.96 Million USD	567.68%
2020 Q4	462.51 Million USD	31.78%
2020 Q1	26.27 Million USD	-29.98%
2019 Q2	40.02 Million USD	-9.46%
2019 FY	148.25 Million USD	-28.79%
2019 Q4	37.52 Million USD	41.54%
2019 Q1	44.2 Million USD	-16.02%
2019 Q3	26.51 Million USD	-33.76%
2018 FY	208.2 Million USD	2.62%
2018 Q4	52.63 Million USD	6.05%
2018 Q3	49.63 Million USD	-5.93%
2018 Q2	52.76 Million USD	-0.75%
2018 Q1	53.16 Million USD	-8.64%
2017 Q4	58.19 Million USD	16.44%
2017 Q1	46.5 Million USD	-21.77%
2017 FY	202.88 Million USD	-28.68%
2017 Q2	48.2 Million USD	3.65%
2017 Q3	49.98 Million USD	3.69%
2016 FY	284.46 Million USD	47.02%
2016 Q3	66.53 Million USD	-15.78%
2016 Q2	79 Million USD	-0.6%
2016 Q4	59.44 Million USD	-10.66%
2016 Q1	79.48 Million USD	-6.22%
2015 Q2	32.13 Million USD	1.26%
2015 FY	193.48 Million USD	94.73%
2015 Q4	84.75 Million USD	129.21%
2015 Q1	31.73 Million USD	-10.75%
2015 Q3	36.97 Million USD	15.09%
2014 Q2	21 Million USD	11.59%
2014 Q3	23.97 Million USD	14.13%
2014 FY	99.36 Million USD	52.57%
2014 Q4	35.55 Million USD	48.28%
2014 Q1	18.82 Million USD	-7.71%
2013 Q3	17.8 Million USD	20.33%
2013 FY	65.12 Million USD	75.79%
2013 Q2	14.79 Million USD	22.03%
2013 Q1	12.12 Million USD	0.14%
2013 Q4	20.39 Million USD	14.56%
2012 FY	37.04 Million USD	26.6%
2012 Q4	12.1 Million USD	37.98%
2012 Q2	7.84 Million USD	-5.8%
2012 Q1	8.32 Million USD	168.4%
2012 Q3	8.77 Million USD	11.94%
2011 Q1	8.26 Million USD	16.67%
2011 FY	29.26 Million USD	-24.65%
2011 Q4	3.1 Million USD	-65.45%
2011 Q3	8.97 Million USD	0.61%
2011 Q2	8.92 Million USD	7.96%
2010 Q3	10.71 Million USD	13.08%
2010 Q2	9.47 Million USD	-18.06%
2010 Q4	7.08 Million USD	-33.89%
2010 Q1	11.56 Million USD	-18.72%
2010 FY	38.83 Million USD	2.99%
2009 Q2	7.85 Million USD	9.79%
2009 Q1	7.15 Million USD	-22.87%
2009 FY	37.7 Million USD	6.45%
2009 Q4	14.22 Million USD	68.12%
2009 Q3	8.46 Million USD	7.69%
2008 Q2	8.54 Million USD	11.31%
2008 Q1	7.67 Million USD	34.35%
2008 FY	35.42 Million USD	12.23%
2008 Q3	9.92 Million USD	16.08%
2008 Q4	9.28 Million USD	-6.45%
2007 Q4	5.71 Million USD	-39.69%
2007 Q3	9.47 Million USD	18.04%
2007 Q2	8.02 Million USD	-2.76%
2007 Q1	8.25 Million USD	56.39%
2007 FY	31.56 Million USD	38.33%
2006 Q1	4.79 Million USD	192.45%
2006 Q4	5.27 Million USD	-7.66%
2006 FY	22.81 Million USD	111.9%
2006 Q3	5.71 Million USD	-14.87%
2006 Q2	6.71 Million USD	40.21%
2005 Q4	-5.18 Million USD	-270.65%
2005 FY	10.76 Million USD	-63.17%
2005 Q3	3.03 Million USD	-44.93%
2005 Q2	5.51 Million USD	-25.5%
2005 Q1	7.4 Million USD	-30.14%
2004 Q4	10.59 Million USD	305.98%
2004 Q1	7.85 Million USD	22.04%
2004 FY	29.23 Million USD	13.39%
2004 Q3	2.6 Million USD	-70.5%
2004 Q2	8.84 Million USD	12.62%
2003 Q3	6.46 Million USD	-0.78%
2003 FY	25.78 Million USD	-21.88%
2003 Q1	6.36 Million USD	8.55%
2003 Q2	6.51 Million USD	2.48%
2003 Q4	6.43 Million USD	-0.51%
2002 Q3	8.04 Million USD	-10.33%
2002 Q2	8.97 Million USD	-11.45%
2002 Q4	5.86 Million USD	-27.15%
2002 Q1	10.13 Million USD	26.02%
2002 FY	33 Million USD	12.76%
2001 Q2	8.56 Million USD	40.98%
2001 Q1	6.07 Million USD	-1.62%
2001 Q3	6.58 Million USD	-23.09%
2001 FY	29.26 Million USD	85.12%
2001 Q4	8.03 Million USD	22.02%
2000 Q2	3.51 Million USD	55.23%
2000 Q3	3.84 Million USD	9.38%
2000 Q4	6.17 Million USD	60.46%
2000 FY	15.81 Million USD	155.02%
2000 Q1	2.26 Million USD	19.32%
1999 Q2	1.1 Million USD	0.0%
1999 Q4	1.9 Million USD	-9.52%
1999 Q3	2.1 Million USD	90.91%
1999 Q1	1.1 Million USD	-45.0%
1999 FY	6.2 Million USD	0.0%
1998 Q2	1.5 Million USD	25.0%
1998 Q3	1.5 Million USD	0.0%
1998 Q4	2 Million USD	33.33%
1998 FY	6.2 Million USD	10.71%
1998 Q1	1.2 Million USD	-20.0%
1997 Q2	1.4 Million USD	7.69%
1997 Q3	1.4 Million USD	0.0%
1997 FY	5.6 Million USD	-5.08%
1997 Q4	1.5 Million USD	7.14%
1997 Q1	1.3 Million USD	-31.58%
1996 Q3	1.2 Million USD	-20.0%
1996 Q1	1.3 Million USD	0.0%
1996 Q4	1.9 Million USD	58.33%
1996 Q2	1.5 Million USD	15.38%
1996 FY	5.9 Million USD	0.0%

Peer Operating Expenses Comparison of Novavax, Inc.

Name	Operating Expenses	Operating Expenses Difference
BioNTech SE	2.52 Billion EUR	69.19%
CureVac N.V.	211.75 Million EUR	-267.939%
Biotest Aktiengesellschaft	136.8 Million EUR	-469.536%
Biotest Aktiengesellschaft	136.8 Million EUR	-469.536%
BRAIN Biotech AG	24.94 Million EUR	-3023.872%
Formycon AG	23.73 Million EUR	-3182.876%
Heidelberg Pharma AG	27.81 Million EUR	-2701.008%
Medigene AG	20.54 Million EUR	-3693.208%

Global Stocks Search

Novavax, Inc. (NVV1.F)

Operating Expenses Summary of Novavax, Inc.

Annual Operating Expenses Chart of Novavax, Inc. (2023 - 1996)

Historical Annual Operating Expenses of Novavax, Inc. (2023 - 1996)

Peer Operating Expenses Comparison of Novavax, Inc.